Investor Presentaiton

Novo Nordisk at a glance Investor presentation Full year 2018 Slide 22 • Global leader in diabetes care and obesity A focused pharmaceutical company with leading positions in diabetes, obesity, haemophilia and growth hormone • Significant growth opportunities driven by the diabetes pandemic, fuelled by global presence and strong research and development pipeline • High barriers to entry in biologics • Operating profit growth targeting 5% yearly on average (measured in local currencies) Earnings conversion to cash targeting 85% • Cash generated returned to shareholders Global insulin market leadership Global insulin market share: 46% Region Europe: Market share 43% North America Operations: Market share 40% Region China: Market share 51% Region Japan & Korea: Market share 50% Region AAMEO: Market share 57% Region Latin America: Market share 46% Global/regional headquarter Source: IQVIA MAT Nov 2018 volume figures AAMEO: Africa, Asia, the Middle East & Oceania Manufacturing R&D facility changing diabetes novo nordisk

View entire presentation